Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B

Antiviral treatment from hepatitis B envelope antigen (HBeAg)-positive status may attenuate the integration of hepatitis B virus DNA into the host genome causing hepatocellular carcinoma (HCC). We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC.

Source: Clinical Gastroenterology and Hepatology - September 5, 2021 Category: Gastroenterology Authors: Heejoon Jang, Jun Sik Yoon, Soo Young Park, Han Ah Lee, Myoung-jin Jang, Seung Up Kim, Dong Hyun Sinn, Yeon Seok Seo, Hwi Young Kim, Sung Eun Kim, Dae Won Jun, Eileen L. Yoon, Joo Hyun Sohn, Sang Bong Ahn, Jae-Jun Shim, Soung Won Jeong, Yong Kyun Cho, Hyo Source Type: research